1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and
Jemal A: Global cancer statistics 2018: GLOBOCAN estimates
of incidence and mortality worldwide for 36 cancers in 185 coun‑
tries. CA Cancer J Clin 68: 394‑424, 2018.
10
TAKAHASHI et al: ROLE OF FDX1 IN CISPLATIN-RESISTANT OVARIAN CANCER
2. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL and
Montz FJ: Survival effect of maximal cytoreductive surgery
for advanced ovarian carcinoma during the platinum era:
A meta‑analysis. J Clin Oncol 20: 1248‑1259, 2002.
3. Bookman MA, Brady MF, McGuire WP, Harper PG,
Alberts DS, Friedlander M, Colombo N, Fowler JM, Argenta PA,
De Geest K, et al: Evaluation of new platinum‑based treatment
regimens in advanced‑stage ovarian cancer: A phase III trial of the
gynecologic cancer intergroup. J Clin Oncol 27: 1419‑1425, 2009.
4. Wilson MK, Pujade‑Lauraine E, Aoki D, Mirza MR, Lorusso D,
Oza AM, du Bois A, Vergote I, Reuss A, Bacon M, et al: Fifth
ovarian cancer consensus conference of the gynecologic cancer
Intergroup: Recurrent disease. Ann Oncol 28: 727‑732, 2017.
5. Beesley VL, Green AC, Wyld DK, O'Rourke P, Wockner LF,
D eFa z io A, Butow PN, P r ic e M A, Hor wo o d K R,
Clavarino AM, et al: Quality of life and treatment response
among women with platinum‑resistant versus platinum‑sensitive
ovarian cancer treated for progression: A prospective analysis.
Gynecol Oncol 132: 130‑136, 2014.
6. Pujade‑Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A,
Kristensen G, Sorio R, Vergote I, Witteveen P, Bamias A, et al:
Bevacizumab combined with chemotherapy for platinumresistant recurrent ovarian cancer: The AURELIA open‑label
randomized phase III trial. J Clin Oncol 32: 1302‑1308, 2014.
7. Marabelle A, Le DT, Ascierto PA, Di Giacomo AM,
De Jesus‑Acosta A, Delord JP, Geva R, Gottfried M, Penel N,
Hansen AR, et al: Efficacy of pembrolizumab in patients
with noncolorectal high microsatellite instability/mismatch
repair‑deficient cancer: Results from the phase II KEYNOTE‑158
study. J Clin Oncol 38: 1‑10, 2020.
8. Stockwell BR, Friedmann Angeli JP, Bayir H, Bush AI, Conrad M,
Dixon SJ, Fulda S, Gascón S, Hatzios SK, Kagan VE, et al:
Ferroptosis: A regulated cell death nexus linking metabolism,
redox biology, and disease. Cell 171: 273‑285, 2017.
9. Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM,
Gleason CE, Patel DN, Bauer AJ, Cantley AM, Yang WS, et al:
Ferroptosis: An iron‑dependent form of nonapoptotic cell death.
Cell 149: 1060‑1072, 2012.
10. Li Y, Feng D, Wang Z, Zhao Y, Sun R, Tian D, Liu D, Zhang F,
Ning S, Yao J and Tian X: Ischemia‑induced ACSL4 activation
contributes to ferroptosis‑mediated tissue injury in intestinal
ischemia/reperfusion. Cell Death Differ 26: 2284‑2299, 2019.
11. Derry PJ, Hegde ML, Jackson GR, Kayed R, Tour JM, Tsai AL
and Kent TA: Revisiting the intersection of amyloid, patho‑
logically modified tau and iron in Alzheimer's disease from a
ferroptosis perspective. Prog Neurobiol 184: 101716, 2020.
12. Lang X, Green MD, Wang W, Yu J, Choi JE, Jiang L, Liao P,
Zhou J, Zhang Q, Dow A, et al: Radiotherapy and immunotherapy
promote tumoral lipid oxidation and ferroptosis via synergistic
repression of SLC7A11. Cancer Discov 9: 1673‑1685, 2019.
13. Guo J, Xu B, Han Q, Zhou H, Xia Y, Gong C, Dai X, Li Z and
Wu G: Ferroptosis: A novel anti‑tumor action for cisplatin.
Cancer Res Treat 50: 445‑460, 2018.
14. Xie Y, Hou W, Song X, Yu Y, Huang J, Sun X, Kang R and
Tang D: Ferroptosis: Process and function. Cell Death Differ 23:
369‑379, 2016.
15. Yang WS, SriRamaratnam R, Welsch ME, Shimada K,
Skouta R, Viswanathan VS, Cheah JH, Clemons PA, Shamji AF,
Clish CB, et al: Regulation of ferroptotic cancer cell death by
GPX4. Cell 156: 317‑331, 2014.
16. Xie Z, Hou H, Luo D, An R, Zhao Y and Qiu C: ROS‑dependent
l ipid p erox id at ion a nd rel ia nt a nt iox id a nt fer rop ‑
tosis‑suppressor‑protein 1 in rheumatoid arthritis: A covert clue
for potential therapy. Inflammation 44: 35‑47, 2021.
17. Bersuker K, Hendricks JM, Li Z, Magtanong L, Ford B, Tang PH,
Roberts MA, Tong B, Maimone TJ, Zoncu R, et al: The CoQ
oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis.
Nature 575: 688‑692, 2019.
18. Doll S, Freitas FP, Shah R, Aldrovandi M, da Silva MC,
Ingold I, Goya Grocin A, Xavier da Silva TN, Panzilius E,
Scheel CH, et al: FSP1 is a glutathione‑independent ferroptosis
suppressor. Nature 575: 693‑698, 2019.
19. Ikeda Y, Hamano H, Horinouchi Y, Miyamoto L, Hirayama T,
Nagasawa H, Tamaki T and Tsuchiya K: Role of ferroptosis in
cisplatin‑induced acute nephrotoxicity in mice. J Trace Elem
Med Biol 67: 126798, 2021.
20. Sato M, Kusumi R, Hamashima S, Kobayashi S, Sasaki S,
Komiyama Y, Izumikawa T, Conrad M, Bannai S and Sato H:
The ferroptosis inducer erastin irreversibly inhibits system xc‑
and synergizes with cisplatin to increase cisplatin's cytotoxicity
in cancer cells. Sci Rep 8: 968, 2018.
21. Wu X, Shen S, Qin J, Fei W, Fan F, Gu J, Shen T, Zhang T and
Cheng X: High co‑expression of SLC7A11 and GPX4 as a predictor
of platinum resistance and poor prognosis in patients with epithe‑
lial ovarian cancer. BJOG 129 (Suppl 2): S40‑S49, 2022.
22. Grinberg AV, Hannemann F, Schiffler B, Müller J, Heinemann U
and Bernhardt R: Adrenodoxin: Structure, stability, and electron
transfer properties. Proteins 40: 590‑612, 2000.
23. Sheftel AD, Stehling O, Pierik AJ, Elsässer HP, Mühlenhoff U,
Webert H, Hobler A, Hannemann F, Bernhardt R and Lill R:
Humans possess two mitochondrial ferredoxins, Fdx1 and Fdx2,
with distinct roles in steroidogenesis, heme, and Fe/S cluster
biosynthesis. Proc Natl Acad Sci USA 107: 11775‑11780, 2010.
24. Shi Y, Ghosh M, Kovtunovych G, Crooks DR and Rouault TA:
Both human ferredoxins 1 and 2 and ferredoxin reductase are
important for iron‑sulfur cluster biogenesis. Biochim Biophys
Acta 1823: 484‑492, 2012.
25. Zhang C, Zeng Y, Guo X, Shen H, Zhang J, Wang K, Ji M and
Huang S: Pan‑cancer analyses confirmed the cuproptosis‑related
gene FDX1 as an immunotherapy predictor and prognostic
biomarker. Front Genet 13: 923737, 2022.
26. Zhang Z, Ma Y, Guo X, Du Y, Zhu Q, Wang X and Duan C:
FDX1 can impact the prognosis and mediate the metabolism of
lung adenocarcinoma. Front Pharmacol 12: 749134, 2021.
27. Okamoto D, Yamauchi N, Takiguchi G, Nishita M, Kakeji Y,
Minami Y and Kamizaki K: Autonomous and intercellular
chemokine signaling elicited from mesenchymal stem cells regu‑
lates migration of undifferentiated gastric cancer cells. Genes
Cells 27: 368‑375, 2022.
28. Avincsal MO, Kamizaki K, Jimbo N, Shinomiya H, Nibu KI,
Nishita M and Minami Y: Oncogenic E6 and/or E7 proteins drive
proliferation and invasion of human papilloma virus‑positive
head and neck squamous cell cancer through upregulation of
Ror2 expression. Oncol Rep 46: 148, 2021.
29. Behrens BC, Hamilton TC, Masuda H, Grotzinger KR,
Whang‑Peng J, Louie KG, Knutsen T, McKoy WM, Young RC
and Ozols RF: Characterization of a cis‑diamminedichloroplat
inum(II)‑resistant human ovarian cancer cell line and its use in
evaluation of platinum analogues. Cancer Res 47: 414‑418, 1987.
30. Chen L, Min J and Wang F: Copper homeostasis and cuproptosis
in health and disease. Signal Transduct Target Ther 7: 378, 2022.
31. Tsvetkov P, Coy S, Petrova B, Dreishpoon M, Verma A,
Abdusamad M, Rossen J, Joesch‑Cohen L, Humeidi R,
Spangler RD, et al: Copper induces cell death by targeting
lipoylated TCA cycle proteins. Science 375: 1254‑1261, 2022.
32. Gao M, Yi J, Zhu J, Minikes AM, Monian P, Thompson CB
and Jiang X: Role of mitochondria in ferroptosis. Mol Cell 73:
354‑363.e3, 2019.
33. Siddik ZH: Cisplatin: Mode of cytotoxic action and molecular
basis of resistance. Oncogene 22: 7265‑7279, 2003.
34. Wang D and Lippard SJ: Cellular processing of platinum anti‑
cancer drugs. Nat Rev Drug Discov 4: 307‑320, 2005.
35. Ciriello G, Miller ML, Aksoy BA, Senbabaoglu Y, Schultz N and
Sander C: Emerging landscape of oncogenic signatures across
human cancers. Nat Genet 45: 1127‑1133, 2013.
36. Cancer Genome Atlas Research Network: Integrated genomic
analyses of ovarian carcinoma. Nature 474: 609‑615, 2011.
37. Hollis RL, Thomson JP, Stanley B, Churchman M, Meynert AM,
Rye T, Bartos C, Iida Y, Croy I, Mackean M, et al: Molecular
stratification of endometrioid ovarian carcinoma predicts clinical
outcome. Nat Commun 11: 4995, 2020.
38. Noriega‑Rivera R, Rivera‑Serrano M, Rabelo‑Fernandez RJ,
Pérez‑Santiago J, Valiyeva F and Vivas‑Mejía PE: Upregulation of
the long noncoding RNA CASC10 promotes cisplatin resistance
in high‑grade serous ovarian cancer. Int J Mol Sci 23: 7737, 2022.
39. Viscarra T, Buchegger K, Jofre I, Riquelme I, Zanella L, Abanto M,
Parker AC, Piccolo SR, Roa JC, Ili C and Brebi P: Functional and
transcriptomic characterization of carboplatin‑resistant A2780
ovarian cancer cell line. Biol Res 52: 13, 2019.
40. Sun J, Cai X, Yung MM, Zhou W, Li J, Zhang Y, Li Z, Liu SS,
Cheung ANY, Ngan HYS, et al: miR‑137 mediates the functional
link between c‑Myc and EZH2 that regulates cisplatin resistance
in ovarian cancer. Oncogene 38: 564‑580, 2019.
41. Meng Y, Chen CW, Yung MMH, Sun W, Sun J, Li Z, Li J, Li Z,
Zhou W, Liu SS, et al: DUOXA1‑mediated ROS production
promotes cisplatin resistance by activating ATR‑Chk1 pathway
in ovarian cancer. Cancer Lett 428: 104‑116, 2018.
This work is licensed under a Creative Commons
Attribution-NonCommercial-NoDerivatives 4.0
International (CC BY-NC-ND 4.0) License.
...
論文の公開元へ
